» Articles » PMID: 20955176

Expression of the Cannabinoid System in Muscle: Effects of a High-fat Diet and CB1 Receptor Blockade

Abstract

The ECS (endocannabinoid system) plays an important role in the onset of obesity and metabolic disorders, implicating central and peripheral mechanisms predominantly via CB1 (cannabinoid type 1) receptors. CB1 receptor antagonist/inverse agonist treatment improves cardiometabolic risk factors and insulin resistance. However, the relative contribution of peripheral organs to the net beneficial metabolic effects remains unclear. In the present study, we have identified the presence of the endocannabinoid signalling machinery in skeletal muscle and also investigated the impact of an HFD (high-fat diet) on lipid-metabolism-related genes and endocannabinoid-related proteins. Finally, we tested whether administration of the CB1 inverse agonist AM251 restored the alterations induced by the HFD. Rats were fed on either an STD (standard/low-fat diet) or an HFD for 10 weeks and then treated with AM251 (3 mg/kg of body weight per day) for 14 days. The accumulated caloric intake was progressively higher in rats fed on the HFD than the STD, resulting in a divergence in body weight gain. AM251 treatment reduced accumulated food/caloric intake and body weight gain, being more marked in rats fed on the HFD. CB2 (cannabinoid type 2) receptor and PPARα (peroxisome-proliferator-activated receptor α) gene expression was decreased in HFD-fed rats, whereas MAGL (monoglyceride lipase) gene expression was up-regulated. These data suggest an altered endocannabinoid signalling as a result of the HFD. AM251 treatment reduced CB2 receptor, PPARγ and AdipoR1 (adiponectin receptor 1) gene expression in STD-fed rats, but only partially normalized the CB2 receptor in HFD-fed rats. Protein levels corroborated gene expression results, but also showed a decrease in DAGL (diacylglycerol) β and DAGLα after AM251 treatment in STD- and HFD-fed rats respectively. In conclusion, the results of the present study indicate a diet-sensitive ECS in skeletal muscle, suggesting that blockade of CB1 receptors could work towards restoration of the metabolic adaption imposed by diet.

Citing Articles

Impact of CB1 receptor antagonism on skeletal muscle hypertrophy and metabolic health: a systematic review of preclinical studies.

de Abreu Junior N, Feltrin I, Pereira D, Bezerra P, Aguiar Jr A Hormones (Athens). 2025; .

PMID: 39869298 DOI: 10.1007/s42000-025-00628-4.


Comparative transcriptomics of broad-spectrum and synthetic cannabidiol treated C2C12 skeletal myotubes.

Gillham S, Cole P, Viggars M, Nolan A, Close G, Owens D Physiol Rep. 2024; 12(18):e70059.

PMID: 39289171 PMC: 11407902. DOI: 10.14814/phy2.70059.


Effect of CB1 Receptor Deficiency on Mitochondrial Quality Control Pathways in Gastrocnemius Muscle.

Senese R, Petito G, Silvestri E, Ventriglia M, Mosca N, Potenza N Biology (Basel). 2024; 13(2).

PMID: 38392333 PMC: 10886598. DOI: 10.3390/biology13020116.


Cancer-Cachexia-Induced Human Skeletal Muscle Myotube Degeneration Is Prevented via Cannabinoid Receptor 2 Agonism In Vitro.

Noone J, Rooney M, Karavyraki M, Yates A, OSullivan S, Porter R Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004445 PMC: 10675367. DOI: 10.3390/ph16111580.


Genetic Manipulation of CB1 Cannabinoid Receptors Reveals a Role in Maintaining Proper Skeletal Muscle Morphology and Function in Mice.

Singlar Z, Ganbat N, Szentesi P, Osgonsandag N, Szabo L, Telek A Int J Mol Sci. 2022; 23(24).

PMID: 36555292 PMC: 9779148. DOI: 10.3390/ijms232415653.